Probable Invasive Pulmonary Cryptococcosis and Possible Cryptococcal Empyema in CLL Treated With Frontline Ibrutinib

Since its approval, a number of case reports have been published detailing the development of fungal infections in patients with relapsed CLL treated with ibrutinib. [...]this case demonstrates that the risk of fungal infection associated with ibrutinib is not limited to patients with relapsed CLL, but is also present with frontline therapy. Amber B. Koehler, PA-C, MS Division of Hematology Mayo Clinic Rochester, MN Prakhar Vijayvargiya, MBBS Division of Infectious Diseases Mayo Clinic Rochester, MN Wei Ding, MBBS, PhD Division of Hematology Mayo Clinic Rochester, MN Potential Competing Interests: Dr Ding has received research funding from Merck, served on the advisory board of Alexion and Merck, and donated to Mayo Clinic.